Every deployment begins with a structured assessment of your brief. Four independent agents then audit it in parallel — regulatory, market, scientific, and competitive — converging on a single verdict: PROCEED, DELAY, or KILL.
Each row below is a decision that either gets made on time, with context — or made late, without it. Everything downstream of that moment compounds.
| Capability | Without AimwellBio | With AimwellBio |
|---|---|---|
| Manual searches. Inconsistent coverage. Signals missed or seen weeks late. | Continuous automated monitoring. Movement detected and contextualized in real time. | |
| Scattered across documents, email, and individual memory. Lost when people leave. | Structured institutional memory that persists through team changes and compounds over time. | |
| Reactive. Based on incomplete data. Often lacks competitive or regulatory context. | Proactive, intelligence-backed decisions informed by structured briefings and continuous signals. | |
| Ad hoc reviews. Guidance changes discovered after they create operational pressure. | Real-time regulatory monitoring. FDA and EMA actions flagged before they affect planning. | |
| Context disappears during personnel transitions. New team members start from scratch. | Preserved organizational intelligence that serves every team member and survives every transition. |
$12–15B repricing inside the 2025–2026 CMS LCD cycle. 86 source-cited signals across PubMed, ClinicalTrials.gov, and SEC. 30 companies under continuous SCOUT monitoring. Refreshed live.
96 source-cited signals. 49 companies under continuous SCOUT monitoring. 18% Saudi diabetes prevalence — Vision 2030 procurement live. The platform that turns indication intelligence into adversarial verification.
146 source-cited signals including 30 SEER cancer-site stat facts. 50 companies under continuous SCOUT monitoring. Population epidemiology layered on adversarial verification — only oncology pipeline carries this.
1,710 source-cited signals across PubMed, ClinicalTrials.gov, FDA, and SEC. 50 companies under continuous SCOUT monitoring across the heart-failure, AFib, and cardiometabolic frontier. Sovereign GCC procurement live.
1,692 source-cited signals. 40 companies under continuous SCOUT monitoring across the CKD, ESRD, dialysis, and transplant frontier. The DKD intersection cross-tagged with the diabetes pipeline. Five sovereign anchors.
1,679 source-cited signals. 50 companies under continuous SCOUT monitoring across the GLP-1, GIP, and MASH frontier. Manufacturing-capacity leading indicators (Catalent, Halozyme). Five sovereign anchors.
Deployments begin with a guided intelligence assessment.